Protease-activated receptor 2-mediated vasodilatation in humans in vivo: Role of nitric oxide and prostanoids

Circulation

Volumn 107, Issue 7, 2003, Pages 954-959

  Robin, Jonathan ^a   Kharbanda, Rajesh ^a   Mclean, Peter ^a   Campbell, Richard ^b   Vallance, Patrick ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Nitric oxide; Prostaglandins; Receptors; Vasodilation

Indexed keywords

NITRIC OXIDE; PROSTANOID; PROTEINASE ACTIVATED RECEPTOR 2; SERINE PROTEINASE;

ARTICLE; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; IN VIVO STUDY; MALE; NORMAL HUMAN; PEPTIDE SYNTHESIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASODILATATION;

ASPIRIN; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLIGOPEPTIDES; OMEGA-N-METHYLARGININE; PROSTAGLANDINS; RECEPTOR, PAR-2; RECEPTORS, THROMBIN; VASODILATION;

EID: 0037465357     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000050620.37260.75     Document Type: Article

References (36)

1. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
2. Nanevicz T, Wang L, Chen M, et al. Thrombin receptor activating mutations: alteration of an extracellular agonist recognition domain causes constitutive signaling. J Biol Chem. 1996;271:702-706.
3. Cheung WM, Andrade-Gordon P, Derian CK, et al. Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo. Can J Physiol Pharmacol. 1998;76:16-25.
4. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
5. Bohm SK, Kong W, Bromme D, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996;314(pt 3):1009-1016.
6. Coste J, Le-Nguyen D, Castro B, et al. A new peptide coupling reagent devoid of toxic by-product. Tetrahedron Lett. 1990;31:205-208.
7. Bhagat K, Collier J, Vallance P. Vasodilatation to arachidonic acid in humans: an insight into endogenous prostanoids and effects of aspirin. Circulation. 1995;92:2113-2118.
8. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-923.
9. Honing ML, Smits P, Morrison PJ, et al. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension. 2000;35:1314-1318.
10. Hamilton JR, Nguyen PB, Cocks TM. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res. 1998;82:1306-1311.
11. Hamilton JR, Moffatt JD, Frauman AG, et al. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol. 2001:38:108-119.
12. Damiano BP, Cheung WM, Santulli RJ, et al. Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther. 1999;288:671-678.
13. Emilsson K, Wahlestedt C, Sun MK, et al. Vascular effects of proteinaseactivated receptor 2 agonist peptide. J Vasc Res. 1997:34:267-272.
14. Hamilton JR, Frauman AG, Cocks TM. Increased expression of proteaseactivated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res. 2001;89:92-98.
15. Compton SJ, Cairns JA, Palmer KJ, et al. A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J Biol Chem. 2000;275:39207-39212.
16. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
17. Bhagat K, Hingorani AD, Palacios M, et al. Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovasc Res. 1999;41:754-764.
18. Benjamin N, Cockcroft JR, Collier JG, et al. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543-555.
19. Cicala C. Protease activated receptor 2 and the cardiovascular system. Br J Pharmacol. 2002;135:14-20.
20. Cicala C, Pinto A, Bucci M. et al. Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation. 1999;99:2590-2597.
21. McGuire JJ, Hollenberg MD, Andrade-Gordon P, et al. Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol. 2002;135:155-169.
22. Cicala C, Morello S, Santagada V, et al. Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. FASEB J. 2001;15:1433-1435.
23. McLean PG, Aston D, Sarkar D, et al. Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res. 2002;90:465-472.
24. Trottier G, Hollenberg M, Wang X, et al. PAR-2 elicits afferent arteriolar vasodilation by NO-dependent and NO-independent actions. Am J Physiol Renal Physiol. 2002;282:F891-F897.
25. Nystedt S, Emilsson K, Larsson AK, et al. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995;232:84-89.
26. Alm AK, Gagnemo-Persson R, Sorsa T, et al. Extrapancreatic trypsin-2 cleaves proteinase-activated receptor-2. Biochem Biophys Res Commun. 2000;275:77-83.
27. Molino M, Bamathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272:4043-4049.
28. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA. 2000;97:5255-5260.
29. Kawabata A, Kuroda R, Nakaya Y, et al. Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. Biochem Biophys Res Commun. 2001;282:432-435.
30. Lourbakos A, Chinni C, Thompson P, et al. Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis. FEBS Lett. 1998;435:45-48.
31. Kawabata A, Kuroda R, Minami T, et al. Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw. Br J Pharmacol. 1998;125:419-422.
32. Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells: comparison with the thrombin receptor. J Biol Chem. 1996;271:14910-14915.
33. Witte J, Jochum M, Scherer R, et al. Disturbances of selected plasma proteins in hyperdynamic septic shock. Intensive Care Med. 1982;8:215-222.
34. Deby-Dupont G, Haas M, Pincemail J, et al. Immunoreactive trypsin in the adult respiratory distress syndrome. Intensive Care Med. 1984;10:7-12.
35. Hedstrom J, Sainio V, Kemppainen E, et al. Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. BMJ. 1996;313:333-337.
36. Hartwig W, Werner J, Jimenez RE, et al. Trypsin and activation of circulating trypsinogen contribute to pancreatitis-associated lung injury. Am J Physiol. 1999;277(pt 1):GI008-GI016.